CA2680909A1 - Procedes de determination d'une reponse de leucemie myeloide aigue a un traitement avec de la farnesyltransferase - Google Patents

Procedes de determination d'une reponse de leucemie myeloide aigue a un traitement avec de la farnesyltransferase Download PDF

Info

Publication number
CA2680909A1
CA2680909A1 CA002680909A CA2680909A CA2680909A1 CA 2680909 A1 CA2680909 A1 CA 2680909A1 CA 002680909 A CA002680909 A CA 002680909A CA 2680909 A CA2680909 A CA 2680909A CA 2680909 A1 CA2680909 A1 CA 2680909A1
Authority
CA
Canada
Prior art keywords
gene
ras
genes
aml
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002680909A
Other languages
English (en)
Inventor
Mitch Raponi
Yixin Wang
Hongtao Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2680909A1 publication Critical patent/CA2680909A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B26—HAND CUTTING TOOLS; CUTTING; SEVERING
    • B26F—PERFORATING; PUNCHING; CUTTING-OUT; STAMPING-OUT; SEVERING BY MEANS OTHER THAN CUTTING
    • B26F1/00—Perforating; Punching; Cutting-out; Stamping-out; Apparatus therefor
    • B26F1/18—Perforating by slitting, i.e. forming cuts closed at their ends without removal of material
    • B26F1/20—Perforating by slitting, i.e. forming cuts closed at their ends without removal of material with tools carried by a rotating drum or similar support
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D28/00—Shaping by press-cutting; Perforating
    • B21D28/02—Punching blanks or articles with or without obtaining scrap; Notching
    • B21D28/14—Dies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
    • B21D37/00—Tools as parts of machines covered by this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Forests & Forestry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Shaping Metal By Deep-Drawing, Or The Like (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002680909A 2007-03-12 2008-03-13 Procedes de determination d'une reponse de leucemie myeloide aigue a un traitement avec de la farnesyltransferase Abandoned CA2680909A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89430807P 2007-03-12 2007-03-12
US60/894,308 2007-03-12
PCT/US2008/056636 WO2008112749A1 (fr) 2007-03-12 2008-03-13 Procédés de détermination d'une réponse de leucémie myéloïde aiguë à un traitement avec de la farnésyltransférase

Publications (1)

Publication Number Publication Date
CA2680909A1 true CA2680909A1 (fr) 2008-09-18

Family

ID=39759983

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002680909A Abandoned CA2680909A1 (fr) 2007-03-12 2008-03-13 Procedes de determination d'une reponse de leucemie myeloide aigue a un traitement avec de la farnesyltransferase

Country Status (9)

Country Link
EP (1) EP2135073A4 (fr)
JP (1) JP2011512785A (fr)
KR (1) KR20090113972A (fr)
CN (1) CN102317772A (fr)
AU (1) AU2008225130A1 (fr)
BR (1) BRPI0808872A2 (fr)
CA (1) CA2680909A1 (fr)
MX (1) MX2009009841A (fr)
WO (1) WO2008112749A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2354922B1 (es) * 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
AU2011282614B2 (en) * 2010-07-28 2015-11-26 Janssen Pharmaceutica Nv Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
US11559540B2 (en) 2010-07-28 2023-01-24 Janssen Pharmaceutica Nv Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
CN108294839A (zh) * 2018-03-08 2018-07-20 广州燃烧医疗技术开发有限公司 一种稳定的牙种植体设备
CN108500114A (zh) * 2018-03-08 2018-09-07 广州峥航机械设备有限公司 一种高效先进的模具设计和制造技术设备
CN108500113A (zh) * 2018-03-08 2018-09-07 广州峥航机械设备有限公司 一种新型模具设计和制造技术设备
CN108465728A (zh) * 2018-03-08 2018-08-31 佛山尘凡环保科技有限公司 一种高阻尼铜合金材设备
CN108500115A (zh) * 2018-03-08 2018-09-07 广州拓讯安防科技有限公司 一种新型精密成形制造装置
CN108326118A (zh) * 2018-03-08 2018-07-27 佛山尘凡环保科技有限公司 一种新型高阻尼铜合金材设备
CN108481435A (zh) * 2018-03-08 2018-09-04 广州拓讯安防科技有限公司 一种精密成形制造装置
CN108453165A (zh) * 2018-03-08 2018-08-28 广州峥航机械设备有限公司 一种先进的模具设计和制造技术设备
CN108339880A (zh) * 2018-03-08 2018-07-31 佛山尘凡环保科技有限公司 一种低成本的高阻尼铜合金材设备

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040065524A (ko) * 2001-10-30 2004-07-22 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 백혈병을 검사 및 치료하는 방법
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer

Also Published As

Publication number Publication date
MX2009009841A (es) 2009-09-24
AU2008225130A1 (en) 2008-09-18
EP2135073A1 (fr) 2009-12-23
KR20090113972A (ko) 2009-11-03
EP2135073A4 (fr) 2011-09-21
WO2008112749A1 (fr) 2008-09-18
JP2011512785A (ja) 2011-04-28
CN102317772A (zh) 2012-01-11
BRPI0808872A2 (pt) 2014-11-11

Similar Documents

Publication Publication Date Title
JP7055778B2 (ja) ファルネシルトランスフェラーゼ阻害剤に応答する患者を同定するためのアッセイ
Raponi et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
EP2135073A1 (fr) Procedes de determination d'une reponse de leucemie myeloide aigue a un traitement avec de la farnesyltransferase
US12274711B2 (en) Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
MX2014003698A (es) Marcadores de diagnostico.
Zamani et al. miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia
US7932036B1 (en) Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US11685955B2 (en) Method for predicting response of patients with malignant diseases to immunotherapy
EP1611890A1 (fr) Méthodes pour évaluer et traiter le cancer
WO2006066240A2 (fr) Procede d'estimation de patients souffrant d'une leucemie myeloide aigue
US8568968B2 (en) EGFR polymorphisms predict gender-related treatment
HK40009380A (en) Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors
KR20100113972A (ko) 파네실트랜스퍼라제 치료에 대한 급성 골수성 백혈병 반응의 측정 방법
Wan et al. The prevalence of PIK3CA mutations in HR+/HER2–metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)
Raponi et al. A two-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130312

FZDE Discontinued

Effective date: 20151201